March 2, 2021 5:38pm

Discomfort in the market reflects difficulty in identifying trends versus my prognostication of share pricing bending

Pre-open indication results: 12 HITs and 1 MISS

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting! Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion!

The Dow closed DOWN -143.99 points (-0.46%); the S&P closed DOWN -31.53 points (-0.81%) while the Nasdaq closed DOWN -230.04 points (-1.69%)



Indexes closed down as the Dow and S&P had moved up and down on Tuesday while the Nasdaq continued to fold, as the cell and gene therapy sector gave back many of their strong gains from the previous session.

An appropriate quote, “Markets may be trapped in a tug-of-war between what they expect to happen and pandemic-fueled insecurities which are compounded by other, harder to quantify, market impulse,” Chris Hussey, a managing director at Goldman Sachs, said in a note. “On days like today, with no news and little macro to help investors keep the faith, we see ‘what ifs’ emerge — sideways trading, across all sectors, coupled by a pullback in rates.” <CNBC>


RegMed Investors’ (RMi) pre-open: “a case of investing interruptus from the previous session? New highs scare me, they’re usually a recipe for a down slide as both the Dow and the Nasdaq clinched their best trading day since November while the $&P ha its best session since June.”


Pre-open indication results:  12 HITs < SELL: Biostage (BSTG -$0.01 with 275 shares traded); BUY: Applied Genetic Technologies (AGTC +$0.30), MiMedx (MDXG +$0.49), uniQure NV (QURE -$2.08), Regenxbio (RGNX -$1.20); SELL into Strength:  Athersys (ATHX -$0.16), Cellectis SA (CLLS -$0.53), CRISPR Therapeutics (CRSP -$0.48), Editas Medicine (EDIT -$1.20), Fate Therapeutics (FATE -$0.70), Intellia Therapeutics (NTLA -$2.06), Global Blood Therapeutics (GB -$0.45) and 0 MISS< Pluristem (PSTI -$0.07)>


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Tuesday opened negative at 16/17, 1 flat and 1 acquired, stayed negative at the mid-day to 15/18, 1 flat and 1 acquired, closing negative at 8/26 and 1 acquired;


There are clear winners — and losers — heading into the second month and Q1 of 2021.

Jumping with share pricing momentum:

  • Alnylam Pharmaceuticals (ALNY), Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS), bluebird bio (BLUE), Precigen (PGEN), MiMedx (MDXG), Applied Genetic Technologies (AGTC), Chinook Therapeutics (KDNY) to name 8 of the 8 inclining of the 35 covered

Hammered in today’s market:

  • Sage Therapeutics (SAGE), Ultragenyx (RARE), ReNeuron (RENE.L), uniQure NV (QURE), Intellia Therapeutics (NTLA) to name 5 of the 26 declining of the 35 covered


Key metrics:

  • Sector volume was LOW with 4 of the 26-upside having higher than the 3-month average volume with the increased volume of 3 of 8-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 8-upside were +0.75% (KDNY) to +25.82% (SLDB) while the 27-downside ranges from -0.37% (CRSP) to -8.78% (ADVM);


Tuesday’s (8 of 8) incline

  • Alnylam Pharmaceuticals (ALNY +$3.94);
  • Solid Biosciences (SLDB +$2.20);
  • Ionis Pharmaceuticals (IONS +$1.25 after Monday’s +$1.65);
  • bluebird bio (BLUE +$0.69);
  • MiMedx (MDXG +$0.49 after Monday’s +$0.76);
  • Precigen (PGEN +$0.38);
  • Applied Genetic Technologies (AGTC +$0.30 after Monday’s +$0.43);
  • Chinook Therapeutics (KDNY +$0.13);

Tuesday’s (10 of 26) decliners:

  • Sage Therapeutics (SAGE -$3.14 after Monday’s +$2.71);
  • Ultragenyx (RARE -$2.54);
  • ReNeuron (RENE.L -$2.50 after Monday’s -$6.00);
  • uniQure NV (QURE -$2.08);
  • Intellia Therapeutics (NTLA -$2.06 after Monday’s +$3.57);
  • Vericel (VCEL -$1.38 after Monday’s -$0.11);
  • Editas Medicine (EDIT -$1.20 after Monday’s +$3.03);
  • Regenxbio (RGNX -$1.20 after Monday’s +$1.60);
  • Adverum Biotechnologies (ADVM -$1.17);
  • BioLife solutions (BLFS -$1.07 after Monday’s +$1.45);

Closing 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19 infections:

  • Economists who track data on Covid-19 virus infections say they are seeing initial signs that vaccines are having working to cut down on the number of deaths and infection rates in the U.S.

Infection cases <Million>: never to forget …

  • Tuesday 28.66 M cases,
  • Tuesday’s death rate totaled 514,842 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -2.05% and XBI closed down -3.13%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.75 points or +3.21% at 24.10

Upside volume: low

  • Tuesday: 3 out of the 8-upside had higher than the 3-month average volume;

Downside volume: low

  • Tuesday: 4 out of the 26-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Tuesday’s percentage (%) of the 8-upside were +0.75% (KDNY) to +25.82% (SLDB) while the 27-downside ranges from -0.37% (CRSP) to -8.78% (ADVM);

March, the 3rd month of Q1/21:

Tuesday closed negative with 8 advancers, 26 decliners and 1 acquired


The BOTTOM LINE: NOT much has changed, I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run.

There is always a shift going-on however, these last two (2) months continues to leave me … QUESTIONING staying longer than a WEEK as I have said recently - my horizon on Monday is to meet on Friday.

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice, trim and skim … if one can!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.